Last reviewed · How we verify
A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds
This research project is testing a product called AmnioClear™ which is an amniotic membrane graft processed for Liventa Bioscience formerly AFCell Medical. AmnioClear™ allograft human amniotic membrane is regulated solely under section 361 of the Public Health Service Act. The purpose of the study is to see if this treatment works to accelerate the healing time of chronic wounds.
Details
| Lead sponsor | Liventa Bioscience |
|---|---|
| Phase | Phase 4 |
| Status | WITHDRAWN |
Conditions
- Diabetic Foot Ulcers
- Wound Care
Interventions
- AmnioClear™ Human Allograft Amniotic Membrane
Primary outcomes
- Reduction in Wound Size — 12 Weeks
Clinical assessment of wound healing in terms of the reduction in size and shape of the wound over time.
Countries
United States